(Q44989619)

8 December 2017

title

Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin (English)

1 reference

8 December 2017

1 reference

1 reference

Vijayan Balan

1

1 reference

8 December 2017

David Schwartz

2

1 reference

8 December 2017

George Y Wu

3

1 reference

8 December 2017

Andrew J Muir

4

1 reference

8 December 2017

Reem Ghalib

5

1 reference

8 December 2017

John Jackson

6

1 reference

8 December 2017

Emmet B Keeffe

7

1 reference

8 December 2017

Lorenzo Rossaro

8

1 reference

8 December 2017

Alfreda Burnett

9

1 reference

8 December 2017

Betty L Goon

10

1 reference

8 December 2017

Peter J Bowers

11

1 reference

8 December 2017

Gerhard J Leitz

12

1 reference

8 December 2017

HCV Natural History Study Group

13

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

The American Journal of Gastroenterology

8 December 2017

published in

1 reference

8 December 2017

volume

100

1 reference

8 December 2017

issue

2

1 reference

8 December 2017

page(s)

299-307

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

The blood in systemic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Side effects of therapy of hepatitis C and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40757.X

10.1111/J.1572-0241.2005.40757.X

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference